Ascendis Pharma A/S (ASND1N)
BMV
Closed
Aug 21, 2026
Day's Range
4,270.0052 wk Range
4,270.00Overview - ASND1N - Ascendis Pharma A/S
Key Statistics
Valuation
Enterprise Value
5.53T
P/E (Trailing)
‪19.30‬
Price / Book
‪9.86‬
EV / EBITDA
‪1,063.04‬
Profitability
Gross Margin
‪92.89%‬
Profit Margin
‪70.84%‬
Operating Margin
‪64.97%‬
Return on Assets
‪9.58%‬
Return on Equity
‪118.78%‬
Ownership
Shares Outstanding
61.77M
Float
65.64M
Held by Insiders
‪0.78%‬
Held by Institutions
‪103.32%‬
Price stats
50-Day Avg
‪4,270.00‬
200-Day Avg
‪4,270.00‬
Dividends
Payout Ratio
‪0.00%‬
Peers - ASND1N - Ascendis Pharma A/S
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- ASND1NBMVAscendis Pharma A/S+0.00%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt+4.58%52-week change33.44P/E (Trailing)‪32.26%‬Profit Margin
- BNTXNBMVBioNTech SE+4.53%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.+4.43%52-week change192.34P/E (Trailing)‪2.14%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals Inc.+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
- ARWRBMVArrowhead Pharmaceuticals Inc.+0.00%52-week change-45455.00P/E (Trailing)‪-47.79%‬Profit Margin
- BEAMBMVBeam Therapeutics Inc.+28.41%52-week change-560.49P/E (Trailing)‪-55.44%‬Profit Margin
Profile Summary - ASND1N - Ascendis Pharma A/S
About
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company that develops and commercializes therapies for serious diseases using its proprietary TransCon technology platform. The company’s primary focus is on endocrinology rare diseases, where it offers SKYTROFA for pediatric growth hormone deficiency and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
